A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial

European Heart Journal

Volumn 20, Issue 1, 1999, Pages 58-69

  Serruys, P W ^a   Foley, D P ^a   Jackson, G ^b   Bonnier, H ^c   Macaya, C ^d   Vrolix, M ^e   Branzi, A ^f   Shepherd, J ^g   Suryapranata, H ^h   De Feyter, P J ^a   Melkert, R ⁱ   Van Es, G A ⁱ   Pfister, P J ^j  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GUY S HOSPITAL   (United Kingdom)

^c CATHARINA HOSPITAL   (Netherlands)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e St Jans Hospital   (Belgium)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

^h HOSPITAL DE WEEZENLANDEN   (Netherlands)

ⁱ CARDIALYSIS   (Netherlands)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Balloon angioplasty; Fluvastatin; Prevention of restenosis

Indexed keywords

FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INDOLES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032904753     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1150     Document Type: Article

References (30)

1. Brown G, Fischer LD, Schaeffer SM. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 264:1990;3007-3012.
2. Blankenhorn DH. Blood lipids and human atherosclerosis regression: the angiographic evidence. Curr Opin Lipidol. 2:1991;2324-2329.
3. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
4. Corsini A, Mazzotti M, Raitevi M. Relationship between mevalonate pathway and arterial myocyte prolifevatim: in vitro studies with inhibitors of HMG-CoA reductaze. Atherosclerosis. 101:1993;117-125.
5. Soma MR, Donetti E, Parolini C. HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 13:1993;571-578.
6. Ozaki Y, Keane D, Herrman JP. Coronary arteriography for quantitative analysis: an experimental and clinical comparison of cinefilm and video recordings. Am Heart J. 129:1995;471-475.
7. Serruys PW, Rutsch W, Heyndrickx GR. Prevention of restenosis after percutaneous transluminal coronary angi-oplasty with thromboxane A2 receptor blockade. A randomized, double blind, placebo controlled trial. Circulation. 84:1991;1568-1580.
8. Circulation. 86:1992;100-111.
9. Serruys PW, Klein W, Thijssen JPG. Evaluation of Ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: a multicentre randomized double-blind placebo-controlled trial. Circulation. 88:1993;1588-1601.
10. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol. 25:1995;362-369.
11. Foley DP, Bonnier H, Jackson G, Macaya C, Sheperd J, Vrolix M, Serruys PW. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. Am J Cardiol. 73:1994;50D-61D.
12. Lipid Research Clinics Manual of Laboratory Operations. 1975;Government printing office.
13. Herrman JPR, Azar A, Umans VAWM, Boersma E, van Es GA, Serruys PW. Inter- and intra-observer variability in the qualitative categorization of coronary angiograms. Int J Cardiac Imag. 12:1996;21-30.
14. Serruys PW, Foley DP, de Feyter PJ. Quantitative Coronary Angiography in Clinical Practice. 1994;Kluwer Academic Publishers, Dordrecht, Boston, London.
15. Shepherd J. Fibrates and statins in the treatment of hyper-lipidaemia: an appraisal of their efficacy and safety. Eur Heart J. 16:1995;5-13.
16. Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibition of proliferation of arterial smooth muscle cells by Fluvastatin. Lancet. 348:1996;1584.
17. Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation. 90:1994;1239-1251.
18. Weintraub WS, Boccuzzi SJ, Klein JL. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 331:1994;1331-1337.
19. Bertrand ME, McFadden EP, Fruchart JC, Predict trial investigators. Effect of Pravastatin on Angio-graphic restenosis after coronary balloon angioplasty. J Am Coll Cardiol. 30:1997;863-869.
20. Foley DP, Melkert R, Umans VA. Differences in restenosis propensity of devices for transluminal coronary intervention: A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implan-tation and excimer laser angioplasty. Eur Heart J. 1995.
21. Keane D, Haase J, Slager CJ. Comparative validation of quantitative coronary angiography systems. Results and implications from a multicenter study using a standardized approach. Circulation. 91:1995;2174-2183.
22. Wilcox JN, Waksman R, King SB, Scott N. The role of the adventitia in arterial response to angioplasty: the effect of intravascular radiation. Int J Radiation Oncol Biol Phys. 36:1996;789-796.
23. Camenzind E, Bakker WH, Reijs A. Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. Circulation. 96:1997;154-165.
24. Mintz GS, Popma JJ, Pichard AD. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 94:1996;35-43.
25. Hoffmann R, Mintz GS, Dussaillant GR. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 92:1994;1247-1254.
26. Lancet. 344:1995;1383-1389.
27. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
28. Sheperd J, Cobbe M, Ford I. Prevention of heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
29. Colli S, Eligini S, Lalli M. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 17:1997;265-272.
30. Bevilacqua M, Bettica P, Milani M. Effect of Fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol. 79:1997;84-86.